compare tirzepatide and retatrutide vs (2026): Differences in Weight Loss, Metabol – Revolution Health & Wellness difference between semaglutide and tirzepatide

Study: Triple-Hormone-Receptor Agonist Retatrutide for Obesity Journal: New England Journal of Medicine (NEJM) ClinicalTrials ID: NCT04881760 View Full Study Retatrutide is a glucagon, GLP-1, and GIP (triple hormone) receptor agonist being investigated to treat obesity

Specifically, retatrutide simultaneously activates three incretin and metabolic hormone receptors: GLP-1 (glucagon-like peptide-1) receptor which reduces appetite and slows gastric emptying [6] [7] GIP (glucose-dependent insulinotropic polypeptide) receptor which enhances insulin secretion and may improve fat metabolism [9] [10] Glucagon receptor which may increase energy expenditure and, based on early clinical and preclinical data, could promote hepatic fat metabolism This triple-action mechanism sets retatrutide apart from existing approved therapies such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist)

Not nothing

Clinical trials have shown promising results for Tirzepatide, with patients losing an average of 11 to 13.1% of their body weight over six months in a phase 2 trial, and even more encouraging results in phase 3 trials

Antidiabetic drugs with controversial effects on cancer risk SGLT2 inhibitors The current body of research on the relationship between SGLT2 inhibitors and cancer risk remains inconclusive